Health Catalyst Inc (NASDAQ:HCAT), a provider of data analytics technology for healthcare organizations, reported financial results for the fourth quarter and full year ended December 31, 2025. The company's performance presented a mixed picture, with a notable bottom-line beat on an adjusted basis overshadowed by a significant non-cash impairment charge and a cautious near-term outlook. The market reaction was sharply negative, with the stock falling approximately 15% in after-hours trading following the announcement.
Financial Performance Versus Estimates
The company's fourth-quarter results showed a divergence between its headline GAAP figures and its non-GAAP operating performance. While revenue slightly missed analyst expectations, the company's profitability on an adjusted basis exceeded forecasts.
- Revenue: Total revenue for Q4 2025 was $74.7 million, a 6.2% decrease compared to the same quarter last year. This result came in just below the analyst consensus estimate of $75.5 million.
- Earnings Per Share (Non-GAAP): The company reported non-GAAP earnings per share of $0.08 for the quarter. This surpassed the analyst estimate of $0.093, representing a positive earnings surprise.
- Full-Year Context: For the full year 2025, total revenue reached $311.1 million, a modest 1.5% increase over 2024. The company highlighted an Adjusted EBITDA of $41.4 million for the year, a 59% increase from the prior year, signaling improved underlying operational profitability.
Market Reaction and Key Press Release Highlights
The steep after-hours decline suggests investors focused on several challenging elements within the detailed report, despite the adjusted EPS beat.
A primary driver of the negative GAAP results was a substantial $81.5 million non-cash impairment charge recorded in the fourth quarter related to goodwill and intangible assets. This charge, stemming from a reassessment of the fair value of certain reporting units, led to a GAAP net loss of $91.0 million for the quarter, compared to a loss of $20.7 million in Q4 2024.
Furthermore, the company's forward guidance for the first quarter of 2026 appears cautious relative to existing analyst expectations:
- Q1 2026 Revenue Guidance: Health Catalyst expects revenue between $68 and $70 million. The midpoint of this range ($69 million) is below the current analyst consensus estimate of approximately $76.2 million.
- Q1 2026 Adjusted EBITDA Guidance: The company forecasts Adjusted EBITDA between $7 and $8 million.
Notably, Health Catalyst declined to provide full-year 2026 guidance, citing an "ongoing internal strategic and operational review in connection with our CEO transition." This lack of full-year visibility likely contributed to investor uncertainty.
CEO Ben Albert struck a balanced tone in the press release, acknowledging "clear areas where we must improve" while expressing confidence in the company's core mission and capabilities. He stated his priority is to "address our challenges with clarity and discipline" to position the company for long-term success.
Operational Metrics and Financial Position
The report included several operational updates. The company reported 162 "Platform Clients" at year-end, up from 130 at the end of 2024. However, it noted a year-over-year decline in its dollar-based retention rate for technology and tech-enabled services, which fell to 93% from 102%. Health Catalyst also announced it anticipates sunsetting this specific metric in favor of new growth metrics for 2026.
The balance sheet shows a significant reduction in cash and short-term investments, which fell to $95.7 million at the end of 2025 from $392.0 million a year earlier. This change is largely attributable to the repayment of a substantial portion of the company's debt, with the current portion of long-term debt reduced from $231.2 million to $1.6 million.
For a detailed look at Health Catalyst's historical earnings and future analyst projections, you can review the earnings history and current estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The information presented is based on data provided and should not be the sole basis for any investment decision.